Cervical Cancer in Women Aged 35 Years and Younger
- PMID: 26899314
- DOI: 10.1016/j.clinthera.2016.01.024
Cervical Cancer in Women Aged 35 Years and Younger
Abstract
Purpose: Age has been evaluated as a prognostic factor in cervical cancer in both hospital- and population-based studies. Results regarding the relation of age and cervical cancer prognosis are conflicting. This study pursued a contemporary assessment of the association of extreme young age at the time of a cervical cancer diagnosis on survival.
Methods: Institutional review board approval was obtained, and retrospective data collection at 2 academic institutions was performed. Inclusion criteria involved women ≤ 35 years diagnosed with cervical cancer between 1990 and 2012. Data included demographic and prognostic information pertinent to survival and progression. Characteristics of very young (≤ 25 years) and young (>25-35 years) women were compared. Kaplan-Meier estimates, the log-rank test, and Cox proportional hazards modeling were used to assess the association of age, tumor histology, grade, stage, and parametrial involvement with progression-free survival (PFS) and overall survival (OS).
Findings: Incident cases (n = 126) of cervical cancer in patients ≤ 35 years of age were identified of which complete clinical information was available for 114 women. Fifteen percent (17 of 114) were ≤ 25 years, with the remaining 85% (97 of 114) being 26 to 35 years of age. Race, smoking status, and marital status were comparable between the 2 groups. Squamous histology dominated overall (77 of 114; 68%) with adenocarcinoma contributing ~25% (30 of 114; 26%) of cases. The majority (96 of 114, 84%) had either stage 1A (31 of 114, 27%) or 1B (65 of 114, 57%) disease. A log-rank test revealed no evidence to infer a difference in either PFS or OS among the age groups (P = 0.511 and P = 0.340). In a univariate analysis, grade and stage significantly affected OS (P < 0.0001, P = 0.045), and stage significantly affected PFS (P < 0.0001). In multivariate modeling, presence of parametrial involvement and histologic cancer type significantly affected both PFS (P = 0.002, P = 0.001) and OS (P = 0.001, P = 0.001).
Implications: Tumor histology, parametrial involvement, and stage continue to be strong prognosticators for PFS and OS. Progression and survival outcomes are age independent in women with cervical cancer ≤ 35 years of age. Further study of a larger young cohort may potentially yield different outcomes.
Keywords: age; cervical cancer; progression; survival; young women.
Copyright © 2016 Elsevier HS Journals, Inc. All rights reserved.
Comment in
-
Cervical Cancer: The Next Generation of Prevention, Detection, and Treatment.Clin Ther. 2016 Mar;38(3):446-8. doi: 10.1016/j.clinthera.2016.02.013. Clin Ther. 2016. PMID: 26993033 No abstract available.
Similar articles
-
Prognostic value of ABO blood group in patients with early stage cervical cancer treated with radical hysterectomy with pelvic node dissection.Tumour Biol. 2016 Jun;37(6):7421-30. doi: 10.1007/s13277-015-4626-1. Epub 2015 Dec 17. Tumour Biol. 2016. PMID: 26678885
-
Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan.Gynecol Oncol. 1999 May;73(2):184-90. doi: 10.1006/gyno.1999.5364. Gynecol Oncol. 1999. PMID: 10329032
-
FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina.Semin Surg Oncol. 1994 Jan-Feb;10(1):31-46. doi: 10.1002/ssu.2980100107. Semin Surg Oncol. 1994. PMID: 8115784 Review.
-
Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma.J Gynecol Oncol. 2017 Mar;28(2):e19. doi: 10.3802/jgo.2017.28.e19. Epub 2016 Dec 8. J Gynecol Oncol. 2017. PMID: 28028992 Free PMC article.
-
Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma.Cancer. 2003 May 1;97(9):2196-202. doi: 10.1002/cncr.11371. Cancer. 2003. PMID: 12712471 Review.
Cited by
-
Precision medicine in cancer: challenges and recommendations from an EU-funded cervical cancer biobanking study.Br J Cancer. 2016 Dec 6;115(12):1575-1583. doi: 10.1038/bjc.2016.340. Epub 2016 Nov 22. Br J Cancer. 2016. PMID: 27875525 Free PMC article.
-
Single-cell transcriptomics unveils multifaceted immune heterogeneity in early-onset versus late-onset cervical cancer.World J Surg Oncol. 2025 Jan 14;23(1):12. doi: 10.1186/s12957-025-03654-z. World J Surg Oncol. 2025. PMID: 39810181 Free PMC article.
-
Survival of cervical cancer patients at Moi teaching and Referral Hospital, Eldoret in western Kenya.BMC Cancer. 2023 Nov 13;23(1):1104. doi: 10.1186/s12885-023-11506-w. BMC Cancer. 2023. PMID: 37957644 Free PMC article.
-
Cervical Squamous Intraepithelial Lesions Are Associated with Differences in the Vaginal Microbiota of Mexican Women.Microbiol Spectr. 2021 Oct 31;9(2):e0014321. doi: 10.1128/Spectrum.00143-21. Epub 2021 Oct 13. Microbiol Spectr. 2021. PMID: 34643408 Free PMC article.
-
Survival of cervical cancer patients in Brunei Darussalam: 2002-2017.Heliyon. 2023 May 6;9(5):e16080. doi: 10.1016/j.heliyon.2023.e16080. eCollection 2023 May. Heliyon. 2023. PMID: 37215873 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical